While Ethicon’s devices for the procedure have included a warning about the spread of cancerous cells, it has decided to suspend the devices until such time as the FDA clearly defines the risks associated with morcellation, according to the report.
“At Ethicon, our first priority is to our customers and patients,” a company spokesman told the Enquirer.
More Articles on Quality:
5 Tips for Focusing Infection Control Policies
10 Things to Know About Infection Control
ASCA Encourages AHRQ ASC Patient Safety Program Participation
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
